FIELD: biotechnology.
SUBSTANCE: invention can be used in medical practice. A bifunctional polypeptide structure is proposed that contains a peptide-major histocompatibility complex (pMNS) peptide-binding fragment, as well as a PD-1 agonist fragment.
EFFECT: inhibition of the PD-1 signaling pathway used in medicine, in particular in the prevention or treatment of various autoimmune diseases.
19 cl, 4 ex, 4 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| IMMUNOTHERAPY USING ANTIBODIES BINDING PROTEIN 1 OF PROGRAMMED CELL DEATH (PD-1) | 2017 |
|
RU2768404C2 |
| FUSION PROTEIN AND ITS USE | 2020 |
|
RU2811120C2 |
| GENETICALLY MODIFIED ANIMALS OTHER THAN HUMANS FOR PRODUCING THERAPEUTIC ANTIBODIES AGAINST PEPTIDE-MHC COMPLEXES, METHODS FOR PRODUCTION AND VERSIONS OF USE THEREOF | 2019 |
|
RU2819525C2 |
| BISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO PD1 AND LAG3 | 2018 |
|
RU2778805C2 |
| REAGENTS FOR REPRODUCTION OF CELLS EXPRESSING RECOMBINANT RECEPTORS | 2018 |
|
RU2783956C2 |
| SPECIFIC BINDING MOLECULES | 2020 |
|
RU2825837C2 |
| NEW BISPECIFIC POLYPEPTIDE COMPLEXES AGAINST CD3/CD19 | 2018 |
|
RU2788127C2 |
| CHIMERIC ANTIGEN RECEPTORS FOR BCMA AND THEIR USE | 2019 |
|
RU2785658C2 |
| PD1-4-1BBL FUSION PROTEIN AND METHODS OF ITS USE | 2018 |
|
RU2769513C2 |
| IMMUNOTHERAPY USING ANTIBODIES BINDING PROGRAMMED CELL DEATH PROTEIN LIGAND 1 (PD-L1) | 2017 |
|
RU2766582C2 |
